Alessandra Fabbri

Alessandra Fabbri

Auto-generated profile, based on publicly available information

Alessandra Fabbri

Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GBGiulia Bertolini
Giulia Bertolini
LRLuca Roz
Luca Roz
Paola PeregoPaola Perego
Paola Perego
MTMonica Tortoreto
Monica Tortoreto
EFEnrico Fontanella
Enrico Fontanella
GSgabriella sozzi
gabriella sozzi
The identification of lung tumor-initiating cells and associated markers may be useful for optimization of therapeutic approaches and for predictive and prognostic information in lung cancer patients. CD133, a surface glycoprotein linked to organ-specific stem cells, was described as a marker of cancer-initiating cells in different tumor types. Here, we report that a CD133 + , epithelial-specific antigen-positive (CD133 + ESA + ) population is increased in primary nonsmall cell lung cancer (NSCLC) compared with normal lung tissue and has higher tumorigenic potential in SCID mice and expression of genes involved in stemness, adhesion, motility, and drug efflux than the CD133 − counterpart. Cisplatin treatment of lung cancer cells in vitro resulted in enrichment of CD133 + fraction both after acute cytotoxic exposure and in cells with stable cisplatin-resistant phenotype. Subpopulations of CD133 + ABCG2 + and CD133 + CXCR4 + cells were spared by in vivo cisplatin treatment of lung tumor xenografts established from primary tumors. A tendency toward shorter progression-free survival was observed in CD133 + NSCLC patients treated with platinum-containing regimens. Our results indicate that chemoresistant populations with highly tumorigenic and stem-like features are present in lung tumors. The molecular features of these cells may provide the rationale for more specific therapeutic targeting and the definition of predictive factors in clinical management of this lethal disease.

1 May 2012 in European Journal Of Cancer Prevention
Verified
Journal Article
Closed access
UPUgo Pastorino
Ugo Pastorino
MRMarta Rossi
Marta Rossi
VRValentina Rosato
Valentina Rosato
AMAlfonso Marchianò
Alfonso Marchianò
NSNicola Sverzellati
Nicola Sverzellati
Carlo La VecchiaCarlo La Vecchia
Carlo La Vecchia
The efficacy and cost-effectiveness of low-dose spiral computed tomography (LDCT) screening in heavy smokers is currently under evaluation worldwide. Our screening program started with a pilot study on 1035 volunteers in Milan in 2000 and was followed up in 2005 by a randomized trial comparing annual or biennial LDCT with observation, named Multicentric Italian Lung Detection. This included 4099 participants, 1723 randomized to the control group, 1186 to biennial LDCT screening, and 1190 to annual LDCT screening. Follow-up was stopped in November 2011, with 9901 person-years for the pilot study and 17 621 person-years for Multicentric Italian Lung Detection. Forty-nine lung cancers were detected by LDCT (20 in biennial and 29 in the annual arm), of which 17 were identified at baseline examination; 63% were of stage I and 84% were surgically resectable. Stage distribution and resection rates were similar in the two LDCT arms. The cumulative 5-year lung cancer incidence rate was 311/100 000 in the control group, 457 in the biennial, and 620 in the annual LDCT group (P=0.036); lung cancer mortality rates were 109, 109, and 216/100 000 (P=0.21), and total mortality rates were 310, 363, and 558/100 000, respectively (P=0.13). Total mortality in the pilot study was similar to that observed in the annual LDCT arm at 5 years. There was no evidence of a protective effect of annual or biennial LDCT screening. Furthermore, a meta-analysis of the four published randomized trials showed similar overall mortality in the LDCT arms compared with the control arm.

1 February 2009 in The American Journal of Pathology
Verified
Journal Article
Closed access
MMMaria Paola Martelli
Maria Paola Martelli
GSgabriella sozzi
gabriella sozzi
Luis HernándezLuis Hernández
Luis Hernández
VPValentina Pettirossi
Valentina Pettirossi
ANAlba Navarro
Alba Navarro
‪‪‪Brunangelo ‪Falini
‪Brunangelo ‪Falini

1 February 2012 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
GPGiuseppe Pelosi
Giuseppe Pelosi
AFAlessandra Fabbri
Alessandra Fabbri
Fabrizio BianchiFabrizio Bianchi
Fabrizio Bianchi
PMPatrick Maisonneuve
Patrick Maisonneuve
GRGiulio Rossi
Giulio Rossi
MPMauro Papotti
Mauro Papotti

1 February 2001 in Transplantation Proceedings
Verified
Journal Article
Closed access
JCJorgelina Coppa
Jorgelina Coppa
APA Pulvirenti
A Pulvirenti
MSM Schiavo
M Schiavo
RRR Romito
R Romito
PCPaola Collini
Paola Collini
VMVincenzo Mazzaferro
Vincenzo Mazzaferro